CRNA raises NOK 620 million for growth through 2030
CRNA said circVec technology advances showed up to 60x–200x improved gene expression in vivo and it has 23 collaborations underway. The company raised NOK 620 million to fund expanded gene and cell therapy programs through 2030.
Major advances in circVec technology drove strong R&D and business development, with up to 60x—200x improved gene expression demonstrated in vivo and 23 collaborations underway.
NOK 620 million raised secures funding through 2030, enabling expanded programs in gene therapy and cell therapy.Based on…